JP2024510502A - 血漿カリクレインのイミダゾピリジニル阻害剤 - Google Patents

血漿カリクレインのイミダゾピリジニル阻害剤 Download PDF

Info

Publication number
JP2024510502A
JP2024510502A JP2023557351A JP2023557351A JP2024510502A JP 2024510502 A JP2024510502 A JP 2024510502A JP 2023557351 A JP2023557351 A JP 2023557351A JP 2023557351 A JP2023557351 A JP 2023557351A JP 2024510502 A JP2024510502 A JP 2024510502A
Authority
JP
Japan
Prior art keywords
pyridin
cyclopropylimidazo
mmol
methyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510502A5 (https=
JPWO2022197755A5 (https=
Inventor
パパイオアンヌー，ニコラス
マーク トラヴィンス，ジェレミー
ジョセリン フィンク，サラ
マーク エラード，ジョン
レイ，アラステア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2024510502A publication Critical patent/JP2024510502A/ja
Publication of JP2024510502A5 publication Critical patent/JP2024510502A5/ja
Publication of JPWO2022197755A5 publication Critical patent/JPWO2022197755A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023557351A 2021-03-17 2022-03-16 血漿カリクレインのイミダゾピリジニル阻害剤 Pending JP2024510502A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162494P 2021-03-17 2021-03-17
US63/162,494 2021-03-17
PCT/US2022/020474 WO2022197755A1 (en) 2021-03-17 2022-03-16 Imidazopyridinyl inhibitors of plasma kallikrein

Publications (3)

Publication Number Publication Date
JP2024510502A true JP2024510502A (ja) 2024-03-07
JP2024510502A5 JP2024510502A5 (https=) 2025-03-21
JPWO2022197755A5 JPWO2022197755A5 (https=) 2025-03-21

Family

ID=81325446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557351A Pending JP2024510502A (ja) 2021-03-17 2022-03-16 血漿カリクレインのイミダゾピリジニル阻害剤

Country Status (4)

Country Link
EP (1) EP4308227A1 (https=)
JP (1) JP2024510502A (https=)
CN (1) CN117396473A (https=)
WO (1) WO2022197755A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512255A (ja) * 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
JP2012526836A (ja) * 2009-05-13 2012-11-01 アムジエン・インコーポレーテツド Ｐｉｋｋ阻害薬としてのヘテロアリール化合物
JP2017520607A (ja) * 2014-07-17 2017-07-27 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換尿素誘導体及びその薬学的使用
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
EP2627178B1 (en) * 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
BR112023018619A2 (pt) * 2021-03-17 2023-11-28 Takeda Pharmaceuticals Co Inibidores de heteroaril de calicreína plasmática
US20240382482A1 (en) * 2021-03-17 2024-11-21 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512255A (ja) * 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション キナーゼ調節因子としての尿素誘導体
JP2012526836A (ja) * 2009-05-13 2012-11-01 アムジエン・インコーポレーテツド Ｐｉｋｋ阻害薬としてのヘテロアリール化合物
JP2017520607A (ja) * 2014-07-17 2017-07-27 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換尿素誘導体及びその薬学的使用
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
．REGISTRY(STN)[ONLINE]，検索日2024年９月０２日: 26 SEP 2014 RN:1626577-88-5他, JPN7025004933, ISSN: 0005733249 *

Also Published As

Publication number Publication date
WO2022197755A1 (en) 2022-09-22
CN117396473A (zh) 2024-01-12
EP4308227A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
CN114728962B (zh) 血浆激肽释放酶抑制剂及其用途
EP3774797B1 (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
EP3500569B1 (en) 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
EP3350170B1 (en) Heteroaryl compounds as irak inhibitors and uses thereof
AU2016215184B2 (en) Pyridazinone macrocycles as IRAK inhibitors and uses thereof
CA3093802A1 (en) Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
WO2024214038A1 (en) Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
AU2015289044A1 (en) Novel naphthryidines and isoquinolines and their use as CDK8/19 inhibitors
BR112020005934A2 (pt) inibidor de pde9 e uso do mesmo
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
JP2024510502A (ja) 血漿カリクレインのイミダゾピリジニル阻害剤
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
JP7695232B2 (ja) ヘテロアリール血漿カリクレインインヒビター
WO2022197789A1 (en) Polycyclic inhibitors of plasma kallikrein
CN116685585A (zh) 一种高活性的hpk1激酶抑制剂
AU2019215598B2 (en) Quinoline compounds as IRAK inhibitors and uses thereof
CN117396469A (zh) 血浆激肽释放酶的抑制剂
EP4642767A1 (en) Pyrimidine carboxamide compounds
US20240199612A1 (en) Imidazopyridinyl inhibitors of plasma kallikrein
WO2025034537A1 (en) Fluoroalkoxyalkylene-dihydroimidazo[5,1-d]tetrazinone compounds and related compounds and their use in treating medical conditions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316